Ventyx Biosciences (VTYX)
(Real Time Quote from BATS)
$2.10 USD
-0.14 (-6.25%)
Updated Aug 2, 2024 02:54 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Ventyx Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -192.96 | -108.43 | -83.75 | -28.17 | NA |
Depreciation/Amortization & Depletion | 0.94 | 0.47 | 0.03 | 0.00 | NA |
Net Change from Assets/Liabilities | 5.81 | -5.16 | 4.02 | 0.81 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 19.69 | 14.34 | 41.05 | 21.17 | NA |
Net Cash From Operating Activities | -166.52 | -98.77 | -38.65 | -6.20 | NA |
Property & Equipment | -0.51 | -0.28 | -0.26 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 1.90 | 0.00 | NA |
Investments | 101.45 | -74.66 | -216.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | 100.94 | -74.93 | -214.37 | 0.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 53.33 | 167.77 | 323.10 | 0.00 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.45 | 6.13 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | 53.33 | 167.77 | 323.55 | 6.13 | NA |
Effect of Exchange Rate Changes | -0.01 | -0.04 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -12.27 | -5.97 | 70.55 | -0.07 | NA |
Cash at Beginning of Period | 64.82 | 70.79 | 0.24 | 0.31 | NA |
Cash at End of Period | 52.55 | 64.82 | 70.79 | 0.24 | NA |
Diluted Net EPS | -3.30 | -2.07 | -6.65 | NA | NA |
Fiscal Year End for Ventyx Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -38.57 | -192.96 | -146.21 | -92.18 |
Depreciation/Amortization & Depletion | NA | 0.41 | 0.94 | 0.54 | 0.27 |
Net Change from Assets/Liabilities | NA | -13.97 | 5.81 | 15.07 | 1.84 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.51 | 19.69 | 15.74 | 9.87 |
Net Cash From Operating Activities | NA | -47.63 | -166.52 | -114.87 | -80.20 |
Property & Equipment | NA | -0.18 | -0.51 | -0.30 | -0.26 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 41.94 | 101.45 | 55.12 | 16.18 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 41.77 | 100.94 | 54.82 | 15.92 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 96.18 | 53.33 | 52.90 | 51.19 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | -0.15 | -0.07 |
Net Cash from Financing Activities | NA | 96.18 | 53.33 | 52.74 | 51.12 |
Effect of Exchange Rate Changes | NA | -0.01 | -0.01 | 0.07 | 0.06 |
Net Change In Cash & Equivalents | NA | 90.32 | -12.27 | -7.23 | -13.10 |
Cash at Beginning of Period | NA | 52.55 | 64.82 | 64.82 | 64.82 |
Cash at End of Period | NA | 142.87 | 52.55 | 57.59 | 51.72 |
Diluted Net EPS | NA | -0.62 | -0.79 | -0.92 | -0.91 |